ABT 263

Base Information

• Chemical Name: ABT 263
• CAS No.: 923564-51-6
• Molecular Formula: C₄₇H₅₅ClF₃N₅O₆S₃
• Molecular Weight: 974.63
• Hs Code.: 29339900
• Mol file: 923564-51-6.mol

Synonyms:4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide;ABT 263;Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-;ABT-263,Navitoclax;Navitoclax;BenzaMide, 4-(4-((2-(4-chlorophenyl)-5,5-diMe;Navitoclax (ABT-263);(S)-4-(4-((4-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

Chemical Property of ABT 263

Chemical Property:

• Appearance/Colour: pale yellow solid
• Melting Point: 114-116 °C
• Refractive Index: 1.654
• PKA: 4.60±0.10(Predicted)
• PSA: 170.42000
• Density: 1.41 g/cm³
• LogP: 11.39950
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility.: Soluble in DMSO (up to 25 mg/ml).

Purity/Quality:

98% ^*data from raw suppliers

ABT263 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Description: ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2. ABT-263 (923564-51-6) is a potent and selective Bcl-2 family inhibitor / BH3 domain mimetic which binds to Bcl-2, Bcl-xL?and Bcl-w (Ki<1 nM). A useful tool compound which has shown interesting results in various cancer clinical trials.2?Synergizes with deoxyglucose and other agents, inducing apoptosis in cancer cells in a xenograft mouse model.3?A novel senolytic agent, inducing apoptosis preferentially in senescent cells in a cell type-restricted manner.4
• Uses: ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively. A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate.

Technology Process of ABT 263

There total 1 articles about ABT 263 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 84.0%

[4-((R)-3-morpholin-4-yl-1-phenylsulfanyl-methyl-propylamino)-3-trifluoromethanesulfonyl]benzenesulfonamide (1027345-12-5) + 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid (1044598-91-5) → navitoclax (923564-51-6)

Guidance literature:

With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20 ℃; for 36h;

DOI:10.1055/s-2008-1067129

upstream raw materials:

[4-((R)-3-morpholin-4-yl-1-phenylsulfanyl-methyl-propylamino)-3-trifluoromethanesulfonyl]benzenesulfonamide

4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid

Refernces

• 1、 -. "Processes To Make Apoptosis Promoters". Page/Page column 33. . Retrieved 2009/12/28.
• 2、 Park, Cheol-Min,Bruncko, Milan,Adickes, Jessica,Bauch, Joy,Ding, Hong,Kunzer, Aaron,Marsh, Kennan C.,Nimmer, Paul,Shoemaker, Alexander R.,Song, Xiaohong,Tahir, Stephen K.,Tse, Christin,Wang, Xilu,Wendt, Michael D.,Yang, Xiufen,Zhang, Haichao,Fesik, Stephen W.,Rosenberg, Saul H.,Elmore, Steven W.. "Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins". experimental part. p. 6902 - 6915. Retrieved 2009/11/30.